Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition
Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were es...
Saved in:
Published in | Chemical research in toxicology Vol. 37; no. 4; pp. 549 - 560 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
15.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model’s quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model’s performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate k obs < 0.01 min–1), weak positive (0.01 ≤ k obs ≤ 0.025 min–1), or positive (k obs > 0.025 min–1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information. |
---|---|
AbstractList | Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model's quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model's performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate kobs < 0.01 min-1), weak positive (0.01 ≤ kobs ≤ 0.025 min-1), or positive (kobs > 0.025 min-1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information. Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model's quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model's performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate < 0.01 min ), weak positive (0.01 ≤ ≤ 0.025 min ), or positive ( > 0.025 min ) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information. Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of CYP3A4 isoenzyme has been associated with clinically relevant DDI. To overcome potential DDI issues, high-throughput in vitro assays were established to assess the TDI of CYP3A4 during the discovery and lead optimization phases. However, in silico machine learning models would enable an earlier and larger-scale assessment of TDI potential liabilities. For CYP inhibition, most modeling efforts have focused on highly imbalanced and small data sets. Moreover, assay variability is rarely considered, which is key to understand the model’s quality and suitability for decision-making. In this work, machine learning models were built for the prediction of TDI of CYP3A4, evaluated prospectively, and compared to the variability of the experimental assay. Different modeling strategies were investigated to assess their influence on the model’s performance. Through multitask learning, additional data sets were leveraged for model building, coming from public databases, in-house CYP-related assays, or other pharmaceutical companies (federated learning). Apart from the numerical prediction of inactivation rates of CYP3A4 TDI, three-class predictions were carried out, giving a negative (inactivation rate k obs < 0.01 min–1), weak positive (0.01 ≤ k obs ≤ 0.025 min–1), or positive (k obs > 0.025 min–1) output. The final multitask graph neural network model achieved misclassification rates of 8 and 7% for positive and negative TDI, respectively. Importantly, the presented deep learning-based predictions had a similar precision to the reproducibility of in vitro experiments and thus offered great opportunities for drug design, early derisk of DDI potential, and selection of experiments. To facilitate CYP inhibition modeling efforts in the public domain, the developed model was used to annotate ∼16 000 publicly available structures, and a surrogate data set is shared as Supporting Information. |
Author | Trunzer, Markus Fluetsch, Andrin Gerebtzoff, Grégori Rodríguez-Pérez, Raquel |
Author_xml | – sequence: 1 givenname: Andrin surname: Fluetsch fullname: Fluetsch, Andrin – sequence: 2 givenname: Markus surname: Trunzer fullname: Trunzer, Markus – sequence: 3 givenname: Grégori surname: Gerebtzoff fullname: Gerebtzoff, Grégori – sequence: 4 givenname: Raquel orcidid: 0000-0002-2992-3402 surname: Rodríguez-Pérez fullname: Rodríguez-Pérez, Raquel email: raquel.rodriguez_perez@novartis.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38501689$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkMtOwzAQRS0EgvL4BeQlm5Sx3byWqDylIrooCFaR7UyoUWIHO5XK3-OqBZasZnPuHd1zTPats0jIOYMxA84upQ5jvcTOYxjceiw0gIB0j4xYyiFJgcE-GUFRioTz4vWIHIfwAcBiNj8kR6KIRFaUI9JfI_Z0htJbY9_po6uxDXTqul56rOng6M26R286tINs6Yv0RirTmuGLNs7TYYl0HkGjB-MsdQ2dvs3F1YQuYiK5xh5tHZP0wS6NMhvmlBw0sg14trsn5Pn2ZjG9T2ZPdw_Tq1kiJ8CHJMWs4aoBiXVeN6CYyBXTEiaqyEFgnnKe6bQsiiznUgnWYF0KybBgSiuFtTghF9ve3rvPVbRUdSZobFtp0a1Cxcu4n4ssFRHNtqj2LgSPTdXHwdJ_VQyqje0q2q7-bFc72zF4vvuxUh3Wv7EfvRHgW2BT8OFW3sbJ_7V-A3KUlB8 |
CitedBy_id | crossref_primary_10_1038_s41467_024_49979_3 crossref_primary_10_1021_acs_molpharmaceut_3c01124 |
Cites_doi | 10.1038/srep42717 10.26434/chemrxiv-2022-ntd3r 10.1021/ci200028n 10.1017/S0033583515000190 10.1053/cp.1999.v66.a101461 10.1021/acs.jcim.9b00801 10.1021/acs.molpharmaceut.2c00571 10.1021/acs.jcim.7b00088 10.2174/156802606778108951 10.1186/s13321-020-0414-z 10.1124/dmd.105.006874 10.1093/nar/gkr777 10.1016/j.patter.2023.100804 10.1021/acs.jcim.9b00237 10.1016/j.ailsci.2021.100027 10.1109/JPROC.2015.2494218 10.1021/acs.molpharmaceut.2c00680 10.1021/tx700079z 10.1021/acs.jcim.5b00130 10.1021/ci400084k 10.1021/acs.jcim.8b00785 10.1214/ss/1177013815 10.1021/ci200091h 10.1080/1062936X.2017.1399925 10.1021/ci200311w 10.1021/ci200615h 10.1001/jama.287.17.2215 10.1093/nar/gkac956 10.1007/s40262-019-00750-8 10.3109/03602532.2014.1003648 10.1177/1087057104274091 10.1124/dmd.110.037911 10.1016/j.ailsci.2022.100056 10.1007/s10822-005-9013-3 10.1021/acs.jcim.2c00412 10.1016/j.slasd.2024.01.005 10.1016/j.bmc.2021.116388 10.1007/s00216-008-2291-6 10.1517/17425255.3.1.51 10.1023/A:1010933404324 10.1021/mp0700413 |
ContentType | Journal Article |
Copyright | 2024 American Chemical Society |
Copyright_xml | – notice: 2024 American Chemical Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1021/acs.chemrestox.3c00305 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-5010 |
EndPage | 560 |
ExternalDocumentID | 10_1021_acs_chemrestox_3c00305 38501689 d122875611 |
Genre | Journal Article |
GroupedDBID | --- -~X 29B 4.4 55A 5GY 5RE 5VS 7~N AABXI ABJNI ABMVS ABQRX ABUCX ACGFS ACJ ACS ADHLV AEESW AENEX AFEFF AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 CUPRZ EBS ED~ F5P GGK GNL IH9 IHE JG~ LG6 P2P ROL TN5 UI2 UPT VF5 VG9 W1F YZZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a402t-5e6f2bf0aed7df0b137b1ca04b8703e75226c5988672ab31fed93a1e81bcbbed3 |
IEDL.DBID | ACS |
ISSN | 0893-228X |
IngestDate | Sat Aug 17 05:40:31 EDT 2024 Wed Sep 25 14:11:36 EDT 2024 Sat Nov 02 12:31:38 EDT 2024 Fri Sep 20 10:05:55 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a402t-5e6f2bf0aed7df0b137b1ca04b8703e75226c5988672ab31fed93a1e81bcbbed3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2992-3402 |
OpenAccessLink | https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.3c00305 |
PMID | 38501689 |
PQID | 2968923653 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2968923653 crossref_primary_10_1021_acs_chemrestox_3c00305 pubmed_primary_38501689 acs_journals_10_1021_acs_chemrestox_3c00305 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-15 |
PublicationDateYYYYMMDD | 2024-04-15 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Chemical research in toxicology |
PublicationTitleAlternate | Chem. Res. Toxicol |
PublicationYear | 2024 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref45/cit45 ref6/cit6 ref36/cit36 ref3/cit3 ref27/cit27 ref18/cit18 ref11/cit11 ref25/cit25 ref16/cit16 ref29/cit29 ref32/cit32 ref23/cit23 ref39/cit39 ref14/cit14 ref8/cit8 ref5/cit5 ref31/cit31 ref2/cit2 ref43/cit43 ref34/cit34 ref37/cit37 ref28/cit28 ref40/cit40 ref20/cit20 ref17/cit17 ref10/cit10 ref26/cit26 ref35/cit35 ref19/cit19 ref21/cit21 ref12/cit12 ref15/cit15 ref42/cit42 ref46/cit46 ref41/cit41 ref22/cit22 ref13/cit13 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref24/cit24 ref38/cit38 ref44/cit44 ref7/cit7 |
References_xml | – ident: ref42/cit42 doi: 10.1038/srep42717 – ident: ref38/cit38 doi: 10.26434/chemrxiv-2022-ntd3r – ident: ref17/cit17 doi: 10.1021/ci200028n – ident: ref37/cit37 – ident: ref11/cit11 doi: 10.1017/S0033583515000190 – ident: ref9/cit9 doi: 10.1053/cp.1999.v66.a101461 – ident: ref20/cit20 doi: 10.1021/acs.jcim.9b00801 – ident: ref24/cit24 doi: 10.1021/acs.molpharmaceut.2c00571 – ident: ref27/cit27 doi: 10.1021/acs.jcim.7b00088 – ident: ref5/cit5 doi: 10.2174/156802606778108951 – ident: ref12/cit12 doi: 10.1186/s13321-020-0414-z – ident: ref45/cit45 doi: 10.26434/chemrxiv-2022-ntd3r – ident: ref32/cit32 – ident: ref7/cit7 doi: 10.1124/dmd.105.006874 – ident: ref43/cit43 doi: 10.1093/nar/gkr777 – ident: ref33/cit33 – ident: ref22/cit22 doi: 10.1016/j.patter.2023.100804 – ident: ref36/cit36 doi: 10.1021/acs.jcim.9b00237 – ident: ref26/cit26 doi: 10.1016/j.ailsci.2021.100027 – ident: ref35/cit35 doi: 10.1109/JPROC.2015.2494218 – ident: ref40/cit40 doi: 10.1021/acs.molpharmaceut.2c00680 – ident: ref1/cit1 doi: 10.1021/tx700079z – ident: ref34/cit34 – ident: ref16/cit16 doi: 10.1021/acs.jcim.5b00130 – ident: ref23/cit23 doi: 10.1021/ci400084k – ident: ref28/cit28 doi: 10.1021/acs.jcim.8b00785 – ident: ref30/cit30 doi: 10.1214/ss/1177013815 – ident: ref14/cit14 doi: 10.1021/ci200091h – ident: ref15/cit15 doi: 10.1080/1062936X.2017.1399925 – ident: ref18/cit18 doi: 10.1021/ci200311w – ident: ref25/cit25 doi: 10.1021/ci200615h – ident: ref39/cit39 – ident: ref8/cit8 doi: 10.1001/jama.287.17.2215 – ident: ref44/cit44 doi: 10.1093/nar/gkac956 – ident: ref3/cit3 doi: 10.1007/s40262-019-00750-8 – ident: ref2/cit2 doi: 10.3109/03602532.2014.1003648 – ident: ref19/cit19 doi: 10.1177/1087057104274091 – ident: ref10/cit10 doi: 10.1124/dmd.110.037911 – ident: ref46/cit46 doi: 10.1016/j.ailsci.2022.100056 – ident: ref47/cit47 doi: 10.1007/s10822-005-9013-3 – ident: ref41/cit41 doi: 10.1021/acs.jcim.2c00412 – ident: ref29/cit29 doi: 10.1016/j.slasd.2024.01.005 – ident: ref21/cit21 doi: 10.1016/j.bmc.2021.116388 – ident: ref4/cit4 doi: 10.1007/s00216-008-2291-6 – ident: ref6/cit6 doi: 10.1517/17425255.3.1.51 – ident: ref31/cit31 doi: 10.1023/A:1010933404324 – ident: ref13/cit13 doi: 10.1021/mp0700413 |
SSID | ssj0011027 |
Score | 2.4777896 |
Snippet | Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug–drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of... Most drugs are mainly metabolized by cytochrome P450 (CYP450), which can lead to drug-drug interactions (DDI). Specifically, time-dependent inhibition (TDI) of... |
SourceID | proquest crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 549 |
SubjectTerms | Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 Enzyme System - metabolism Deep Learning Drug Interactions Models, Biological Reproducibility of Results |
Title | Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition |
URI | http://dx.doi.org/10.1021/acs.chemrestox.3c00305 https://www.ncbi.nlm.nih.gov/pubmed/38501689 https://search.proquest.com/docview/2968923653 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3fb9MwEMdPY7wgIX4MGOWXDgnthaWL7diJH6du00ACFbGh8hTlYochIKmWVKL89dhxuoJQBbxGsuVczvHHPt_3AF4YVcRUCRYZ4U-rjNQRZZpHypCRiigRfYb3m7fq9Dx5PZOzLYg3RPA5OyhKZ_wL-82Xqmi-j0XZY-81uM5Thw8ehibvr-IGrkXQ9tQi4jybrXKCN_bjF6Wy_X1R2kCa_YpzchverfJ2wkWTL-NFR-Pyx58yjv_8Mnfg1oCfeBj85S5s2XoH9qZBv3q5j2frdKx2H_dwula2Xu7AzXDIhyF36R7Mj6yd4yDR-gl9XbWvLU6Ga-3YNXj8SwEB_OD25UEWfImOldGxJ04vfaTIewc2FU4-TsVhgj4vJToayvN2-Kq--Ez91bL7cH5yfDY5jYYSDlHhNqZdJK2qOFVxYU1qqpiYSImVRZyQ-08Im3r6K6XOMpXyggSrrNGiYNbBdElkjXgA23VT24eAXis-TstYGlU5BpSkmayMtUInKVmejOCls24-TME276PrnOX-4drk-WDyERysvng-D7oef23xfOUYuZuCPq5S1LZZtDnXyrm3UFKMYDd4zFWfIpMOqjP96L9G9xhucAdPPmrF5BPY7i4X9qmDn46e9f7-ExktAvQ |
link.rule.ids | 315,782,786,2767,27083,27931,27932,56745,56795 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8xeNikaRvsg-6LmzTxMlJiO3bix6qACgNUaWXqnqI4dgbaSCqSSpS_fnaStgMJTePVkq2zc5f72Xf3O4DPWiS-yhjxNHOvVZpLT0WSekIrzYVSAasrvE9OxeAsOBrzcft04WphrBClXamsg_hLdgGy68bsNi5dx4riusvSGv0-gjUuwsDl8vX63xbhAzujofiUzKM0Gs9Lg-9dx_mmtLztm-4BnLXjOXgO44XIdb7Jr-60Ut305g6b4wP29AKetWAUe432rMOKyTdge9iwWc92cLQszip3cBuHS57r2QY8bZ78sKlkegmTPWMm2BK2_kTXZe13if02yR2rAvf_aieA3-0tvSEJn6FFzmiRKA6vXNzI6QoWGfZ_DFkvQFel4u21zXorPMzPL1SdaPYKzg72R_2B1zZ08BJ7Ta08bkRGVeYnRoc68xVhoSJp4gfK_jWYCR0WTLmMIhHSRDGSGS1ZQoyF1qlSRrPXsJoXudkEdMzxfpj6XIvMIkKuJOGZNobJIFSGBh34Yk83bg2yjOtYOyWxG1weedweeQd25x8-njQsH_-c8WmuH7E1SBdlSXJTTMuYSmGVnQnOOvCmUZzFmiziFmJH8u1_SbcFjwejk-P4-PD06zt4Qi2scvEswt_DanU1NR8sLKrUx9oE_gBQSAth |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEB_OE0QQH-drfY4g98XrXpM0aYOflt1b7nwcBe9kD4TSNImK2i7XLrj-9SZtd1eFQ_RrIGGSznR-ycz8BuC5FnmoLCOBZv61SnMZqETSQGiluVAqYm2F99tjcXgavZrx2Ra8XNXCOCFqt1LdBvG9Vc-17RkGyL4fd1v55rtWVN-HrGgR8CW4zEUsfT7faPxuHUJwMzqaT8kCSpPZqjz4wnW8fyrq3_3TBaCzdT7TG_BhLXabc_JluGjUsPjxB6Pjf-7rJlzvQSmOOi26BVum3IHdtGO1Xu7hyaZIq97DXUw3fNfLHbjWPf1hV9F0G-YTY-bYE7d-RN9t7WuN4z7ZHZsKD35pK4Dv3W29IwtfokPQ6BAppuc-fuR1BiuL47OUjSL01SrBpG_a2-BR-emzahPO7sDp9OBkfBj0jR2C3F1Xm4AbYamyYW50rG2oCIsVKfIwUu7vwUzsMWHBZZKImOaKEWu0ZDkxDmIXShnN7sJ2WZXmPqBnkA_jIuRaWIcMuZKEW20Mk1GsDI0G8MKdbtYbZp21MXdKMj-4OfKsP_IB7K8-fjbv2D7-OuPZSkcyZ5g-2pKXplrUGZXCKT0TnA3gXqc86zVZwh3UTuSDf5LuKVxJJ9PszdHx64dwlTp05cNahD-C7eZ8YR47dNSoJ60V_ATWXA3k |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deep+Learning+Models+Compared+to+Experimental+Variability+for+the+Prediction+of+CYP3A4+Time-Dependent+Inhibition&rft.jtitle=Chemical+research+in+toxicology&rft.au=Fluetsch%2C+Andrin&rft.au=Trunzer%2C+Markus&rft.au=Gerebtzoff%2C+Gr%C3%A9gori&rft.au=Rodr%C3%ADguez-P%C3%A9rez%2C+Raquel&rft.date=2024-04-15&rft.issn=0893-228X&rft.eissn=1520-5010&rft.volume=37&rft.issue=4&rft.spage=549&rft.epage=560&rft_id=info:doi/10.1021%2Facs.chemrestox.3c00305&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_chemrestox_3c00305 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-228X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-228X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-228X&client=summon |